Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Aridis Pharmaceuticals, Inc. | a2241140zex-32_2.htm |
| EX-31.2 - EX-31.2 - Aridis Pharmaceuticals, Inc. | a2241140zex-31_2.htm |
| EX-31.1 - EX-31.1 - Aridis Pharmaceuticals, Inc. | a2241140zex-31_1.htm |
| EX-23.1 - EX-23.1 - Aridis Pharmaceuticals, Inc. | a2241140zex-23_1.htm |
| EX-21.1 - EX-21.1 - Aridis Pharmaceuticals, Inc. | a2241140zex-21_1.htm |
| EX-4.1 - EX-4.1 - Aridis Pharmaceuticals, Inc. | a2241140zex-4_1.htm |
| 10-K - 10-K - Aridis Pharmaceuticals, Inc. | a2241140z10-k.htm |
QuickLinks -- Click here to rapidly navigate through this document
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Aridis Pharmaceuticals, Inc. (the "Company") for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Vu Truong, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: April 8, 2020 | By: | /s/ VU TRUONG Vu Truong, Ph.D. Chief Executive Officer (Principal Executive Officer) |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002